Skip to content

Study · Case report or series · n = 1 · 2024

1 result

Wernicke Encephalopathy Associated With Semaglutide Use.

Sheth K, Garza E, Saju A, Nazir N, Agarwal A

Cureus6 Jun 2024Cited by 5 (Europe PMC)

PMID38975533 (opens in a new tab)PMCIDPMC11227085 (opens in a new tab)DOI10.7759/cureus.61783 (opens in a new tab)PepBankPUB-38975533
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

A patient presenting to the emergency room with neurological symptoms is more commonly found to have manifestations of stroke, transient ischemic attack, or nervous system injury. Alcoholic Wernicke encephalopathy (WE) is also another common manifestation of neurological dysfunction; however, the prevalence of non-alcoholic WE is relatively uncommon. We discuss a 37-year-old male who presented to the ED with dysphagia, slurred speech, word-finding difficulty, and restricted extraocular movements from non-alcoholic WE in the setting of semaglutide use.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In one 37-year-old man, non-alcoholic Wernicke encephalopathy occurred in the setting of semaglutide use.

    In plain wordsIn one man, a brain condition called Wernicke encephalopathy occurred while he was using semaglutide. This single case does not show cause.

    Peptide
    Semaglutide
    Outcome
    Not applicableWernicke encephalopathy
    Study

    n = 1

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Title
    Wernicke Encephalopathy Associated With Semaglutide Use.
    1 context sentence
    Summary · context
    We discuss a 37-year-old male who presented to the ED with dysphagia, slurred speech, word-finding difficulty, and restricted extraocular movements from non-alcoholic WE in the setting of semaglutide use.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.